HOKUSAI-VTE
2013
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
In 8,240 patients with acute venous thromboembolism after initial heparin, once-daily edoxaban was non-inferior for recurrent symptomatic venous thromboembolism and caused less clinically relevant bleeding than warfarin.
Result
Efficacy: Recurrent symptomatic venous thromboembolismHR 0.89 (95% CI 0.70-1.13) · P < 0.001
Safety: Major or clinically relevant bleedingHR 0.81 (95% CI 0.71-0.94) · P = 0.004
Below 1 favours once-daily edoxaban, above 1 favours warfarin.
Event rates Once-daily edoxaban 3.2% vs warfarin 3.5% (recurrent symptomatic venous thromboembolism)
Also reported: In PE with right-ventricular dysfunction, recurrence 3.3 % vs 6.2 % (HR 0.52).
- Subtopic
- Venous thromboembolism
- Design
- Double-blind, double-dummy non-inferiority RCT
- Relevance
- Important: one of several pillars.
- Source
- The Hokusai-VTE Investigators. N Engl J Med. 2013;369(15):1406-1415.doi 10.1056/NEJMoa1306638
Discussion & critique
A heparin lead-in is mandatory, so this is not a single-drug regimen. Its double-blind design, high-quality warfarin comparator and the pre-specified right-ventricular-dysfunction subgroup make it the strongest DOAC evidence in the sicker end of the PE spectrum.